The management of goal-directed fluid therapy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Abstract

Cytoreductive surgery is a surgical treatment approach that has been applied over the last 3 decades in patients with peritoneal metastases originating from intraabdominal organs. Goal-directed fluid therapy (GDFT) is an approach in which a patient fluid therapy during a medical procedure or surgery is carefully managed based on a specific goal. In this study, we aimed to present the results of GDFT in patients who underwent cytoreductive surgery for peritoneal carcinomatosis (PC) during the perioperative period. This retrospective study included 398 patients patient who underwent cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) due to PC originating from intraabdominal malignancies. Of the cases, 233 (58.6%) were female, and 165 (41.4%) were male patients. The mean age was 58.9. Perioperative findings revealed an average PC score of 12 (3–24), average lactate levels of 3 (2–7) mmol/L, Pao2/fio2 of 3.3 (2.4–4.1) mm Hg, mean arterial pressure (MAP) of 60 (55–70), average surgery duration of 6.5 hours (3–14), and average blood loss of 400 (200–4000) cc. The mean intraoperative fluid rate was 6.4 mL/kg/h (IQR 5.8–7.1). Sixteen (16.3%) patients experienced Clavien-Dindo Grade 3–4 adverse events. Within 30 days, 25 patients (6.3%) died. CRS + HIPEC procedures utilizing perioperative GDFT along with advanced anesthesia monitoring devices have shown successful application, offering an alternative to traditional and restrictive fluid management approaches.